Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274792 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 132
- Enrollment target
NCT02274792: Completed Phase 4 study, sponsored by Amgen.
NCT02274792 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 132 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02274792, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
Primary Outcome
Seroreactivity to etanercept was evaluated using a validated enzyme-linked immunosorbent assay (ELISA).
Interventions
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-11 |
| Phase | Phase 4 |
What the finished NCT02274792 record still lists
NCT02274792 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Etanercept is the first listed.
NCT02274792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02274792 about?
NCT02274792 is a clinical study titled "Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis". The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
What is the current status of trial NCT02274792?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 132 participants. The study started on 2015-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02274792?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT02274792?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02274792's enrollment target sits among peer trials
132 610th of 2000 higher than 1,382 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia